July 2020 Clinical Watch Newsletter

August 4, 2020

In this issue of Clinical Watch, we discuss new antipsychotic medication formulations to tailor the management of schizophrenia and suggest prior authorization criteria for a new treatment for Cushing’s disease. Lastly, we review claims data to identify the trends for use of Dupixent®.
For more information about a topic, please contact Janelle Sheen, Karen Powell or Mary-Beth Plum. Be sure to watch for future monthly updates. For more information about our solutions, please visit conduent.com/pharmacysolutions.

Previous Article
Five Strategies to Bring Your Community Health Needs Assessment to Life
Five Strategies to Bring Your Community Health Needs Assessment to Life

Next Article
Conduent’s New Rank on the Everest Group PEAK Matrix Signals More Value for Our Clients
Conduent’s New Rank on the Everest Group PEAK Matrix Signals More Value for Our Clients